Back to Screener

Healthcare

IXICO plc(PHYOF)

Live Price

Offline

$0.07

+0.00% today

1Y Change

+0.00%

Window

Jun 23, 2025 โ†’ Jun 18, 2026

Market Cap
$10.00M
Revenue Growth
+13.3%
EPS Growth
+55.3%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 23, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

IXICO plc (PHYOF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.07 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +13.3%, EPS growth of +55.3%, a dividend yield of 0.0%. What stands out right now is revenue +13.3%, EPS +55.3%, free cash flow +14.8% with operating margin -34.9% and ROIC -12.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Stock Foundry combines PHYOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+13.3% vs +7.6% peer median

Operating Margin

Below sector median

-34.9% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating story is still moving forward

Revenue is running at +13.3% and EPS at +55.3%, with operating margin around -34.9%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PHYOF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PHYOF Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PHYOF and SPY.

Calendar-year return history is still loading or unavailable.
IXICO plc logo

Company Overview

IXICO plc

Other OTC

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

Leadership
Bram Goorden
IPO Date
Jan 23, 1997
Employees
81
Street Address
Griffin Court
Mailing
London, EC1A 9PN
Region
London, GB
Reporting Currency
USD
Investor Line
44 20 3763 7499
Last Updated
May 3, 2026
ISIN: GB00BFXR4C20
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
1.0
Price/Book
0.5

Growth

Revenue
+13.3%
EPS
+55.3%
Free Cash Flow
+14.8%

Profitability

Gross Margin
47.3%
Operating Margin
-34.9%
Net Margin
-25.3%
ROE
-13.7%
ROIC
-12.9%

Balance Sheet

Debt/Equity
0.02
Current Ratio
3.03

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.